Log in

OTCMKTS:PVCTProvectus Biopharmaceuticals Stock Price, Forecast & News

$0.05
+0.00 (+5.38 %)
(As of 06/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.04
Now: $0.05
$0.05
50-Day Range
$0.04
MA: $0.05
$0.05
52-Week Range
$0.03
Now: $0.05
$0.08
Volume277,397 shs
Average Volume301,394 shs
Market Capitalization$18.36 million
P/E RatioN/A
Dividend YieldN/A
Beta0.4
Provectus Biopharmaceuticals, Inc., a biopharmaceutical company, engages in developing drugs based on halogenated xanthenes for oncology and dermatology indications. Its prescription drug candidates include PV-10, which is in Phase III study for cutaneous melanoma; completed Phase II study for metastatic melanoma; completed Phase I study for liver and breast cancers; and phase 1b/2 study for pembrolizumab. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PVCT
Previous SymbolNYSEMKT:PVCT
CUSIPN/A
Phone866-594-5999

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.06) per share

Profitability

Net Income$-6,920,000.00

Miscellaneous

Employees2
Market Cap$18.36 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive PVCT News and Ratings via Email

Sign-up to receive the latest news and ratings for PVCT and its competitors with MarketBeat's FREE daily newsletter.

Provectus Biopharmaceuticals (OTCMKTS:PVCT) Frequently Asked Questions

How has Provectus Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Provectus Biopharmaceuticals' stock was trading at $0.0445 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PVCT stock has increased by 5.6% and is now trading at $0.0470. View which stocks have been most impacted by Coronavirus.

When is Provectus Biopharmaceuticals' next earnings date?

Provectus Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Provectus Biopharmaceuticals.

Has Provectus Biopharmaceuticals been receiving favorable news coverage?

Press coverage about PVCT stock has been trending very positive recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Provectus Biopharmaceuticals earned a daily sentiment score of 3.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutProvectus Biopharmaceuticals.

Who are some of Provectus Biopharmaceuticals' key competitors?

What other stocks do shareholders of Provectus Biopharmaceuticals own?

Who are Provectus Biopharmaceuticals' key executives?

Provectus Biopharmaceuticals' management team includes the following people:
  • Dr. Timothy C. Scott, Pres (Age 61)
  • Dr. Eric A. Wachter, Co-Founder & Chief Technology Officer (Age 56)
  • Mr. Bruce Horowitz, Chief Operations Consultant & Director (Age 63)
  • Ms. Heather Raines, Chief Financial Officer (Age 52)

What is Provectus Biopharmaceuticals' stock symbol?

Provectus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "PVCT."

How do I buy shares of Provectus Biopharmaceuticals?

Shares of PVCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Provectus Biopharmaceuticals' stock price today?

One share of PVCT stock can currently be purchased for approximately $0.05.

How big of a company is Provectus Biopharmaceuticals?

Provectus Biopharmaceuticals has a market capitalization of $18.36 million. Provectus Biopharmaceuticals employs 2 workers across the globe.

What is Provectus Biopharmaceuticals' official website?

The official website for Provectus Biopharmaceuticals is www.provectusbio.com.

How can I contact Provectus Biopharmaceuticals?

Provectus Biopharmaceuticals' mailing address is 10025 INVESTMENT DRIVE SUITE 250, KNOXVILLE TN, 37932. The company can be reached via phone at 866-594-5999 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.